IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
About IOTA Pharmaceuticals

IOTA’s UK Drug Screening Labs are based in the world-leading hub for cancer biology in Cambridge. With both the CRUK and MRC-LMB laboratories situated in the city, Cambridge is a major European centre for chemical biology.

Through its co-Founder, Dr Paul England, IOTA has considerable experience in high-content, high-throughput compound screening, both at the biochemical and at a functional, cell-based level. Our current screening programmes are focused on oncology with both target based and phenotypic screens for glioblastoma.  

IOTA Target Based Screening Programmes
Proteases Kinases GPCRs
Chemokine Receptors Nuclear Hormone Receptors Nicotinic Receptors